BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whitney Z, Boyda HN, Procyshyn RM, Elbe D, Black T, Eslami A, Barr AM. Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology 2015;25:234-45. [DOI: 10.1089/cap.2014.0044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Varimo E, Aronen ET, Mogk H, Rättö H, Saastamoinen LK. Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study. J Child Adolesc Psychopharmacol 2021;31:421-9. [PMID: 33739863 DOI: 10.1089/cap.2020.0095] [Reference Citation Analysis]
2 Wohkittel C, Gerlach M, Taurines R, Wewetzer C, Unterecker S, Burger R, Schreck D, Mehler-Wex C, Romanos M, Egberts K. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm (Vienna) 2016;123:1021-31. [PMID: 27221285 DOI: 10.1007/s00702-016-1573-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Dodsworth T, Kim DD, Procyshyn RM, Ross CJ, Honer WG, Barr AM. A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health 2018;12:37. [PMID: 30026806 DOI: 10.1186/s13034-018-0243-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
4 Lee ES, Vidal C, Findling RL. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. Journal of Child and Adolescent Psychopharmacology 2018;28:582-605. [DOI: 10.1089/cap.2018.0037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
5 dos Santos-júnior A, Tamascia ML, Lorenzetti R, Della Torre OH, Paes LA, Fontana TS, Ferreira-neto AP, Henriques TB, Hyslop S, de Mello MP, Celeri EHRV, Dalgalarrondo P, Guerra-júnior G. Serum Concentration of Risperidone and Adverse Effects in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 2017;27:211-2. [DOI: 10.1089/cap.2016.0114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Pisano S, Catone G, Veltri S, Lanzara V, Pozzi M, Clementi E, Iuliano R, Riccio MP, Radice S, Molteni M, Capuano A, Gritti A, Coppola G, Milone A, Bravaccio C, Masi G. Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr 2016;42:51. [PMID: 27209326 DOI: 10.1186/s13052-016-0259-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
7 Radhakrishnan V, Pai V, Rajaraman S, Mehra N, Ganesan T, Dhanushkodi M, Perumal Kalaiyarasi J, Rajan AK, Selvarajan G, Ranganathan R, Karunakaran P, Sagar TG. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial. Pediatr Blood Cancer 2020;67:e28532. [PMID: 32568452 DOI: 10.1002/pbc.28532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, Sportiello L, Bertella S, Auricchio F, Bernardini R, Ferrajolo C, Guastella G, Mani E, Carnovale C, Pisano S, Rafaniello C, Riccio MP, Rizzo R, Scuderi MG, Sperandeo S, Villa L, Pascotto A, Molteni M, Rossi F, Radice S, Clementi E. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol 2016;72:285-93. [DOI: 10.1007/s00228-015-1982-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
9 Egberts K, Reuter-Dang SY, Fekete S, Kulpok C, Mehler-Wex C, Wewetzer C, Karwautz A, Mitterer M, Holtkamp K, Boege I, Burger R, Romanos M, Gerlach M, Taurines R. Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care. J Neural Transm (Vienna) 2020;127:1663-74. [PMID: 32997183 DOI: 10.1007/s00702-020-02253-4] [Reference Citation Analysis]
10 Cai Q, Patel C, Kim E, Connolly N, Tunceli O, El Khoury AC. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Adv Ther 2019;36:858-69. [PMID: 30848442 DOI: 10.1007/s12325-019-00913-w] [Reference Citation Analysis]
11 Lee ES, Kronsberg H, Findling RL. Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. Child Adolesc Psychiatr Clin N Am 2020;29:183-210. [PMID: 31708047 DOI: 10.1016/j.chc.2019.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Deng SH, Wang ZZ, Lu HY, Li L, Hu JQ, Zhu XQ, Xie HS, Chen HZ, Zhang M, Ni XJ, Qiu C, Shang DW, Wen YG. A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors. Ther Drug Monit 2020;42:636-42. [PMID: 32039940 DOI: 10.1097/FTD.0000000000000738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Tron C, Kloosterboer SM, van der Nagel BCH, Wijma RA, Dierckx B, Dieleman GC, van Gelder T, Koch BCP. Dried Blood Spots Combined With Ultra-High-Performance Liquid Chromatography-Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites. Ther Drug Monit 2017;39:429-40. [PMID: 28700523 DOI: 10.1097/FTD.0000000000000411] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kloosterboer SM, Vierhout D, Stojanova J, Egberts KM, Gerlach M, Dieleman GC, Hillegers MHJ, Passe KM, Gelder TV, Dierckx B, Koch BCP. Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Expert Opin Drug Saf 2020;19:873-90. [PMID: 32421365 DOI: 10.1080/14740338.2020.1770224] [Reference Citation Analysis]
15 Rafaniello C, Pozzi M, Pisano S, Ferrajolo C, Bertella S, Sportiello L, Carnovale C, Sullo MG, Cattaneo D, Gentili M, Rizzo R, Pascotto A, Mani E, Villa L, Riccio MP, Sperandeo S, Bernardini R, Bravaccio C, Clementi E, Molteni M, Rossi F, Radice S, Capuano A. Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 2016;15:1-8. [PMID: 27875914 DOI: 10.1080/14740338.2016.1229301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
16 Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clin Pharmacokinet 2018;57:1493-528. [DOI: 10.1007/s40262-018-0664-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
17 Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev 2020;52:1-18. [PMID: 32008418 DOI: 10.1080/03602532.2020.1717517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]